文献速递胸部肿瘤放疗

立体定向消融放疗联合手术治疗早期非小细胞肺癌的整合评估:长期临床结局

Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: Long-Term Clinical Outcomes.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-10-01

MISSILE 2期试验纳入40例T1-2N0M0非小细胞肺癌患者,先接受新辅助SABR再行肺叶/楔形切除,36例完成手术;术后中位随访6.6年,5年总生存66.7%、无病生存58.3%、癌症特异性生存76.4%,16.7%患者出现相关≥3级不良事件,无5级事件;作者认为该联合方案安全且长期结局合理,但与单纯手术相似。

要点

  • 40例早期NSCLC接受新辅助SABR,其中36例后续接受手术。
  • 病理完全缓解率60%,主要完全缓解率63%。
  • 5年总生存66.7%、无病生存58.3%、癌症特异性生存76.4%。

核心结论

  • SABR联合手术的治疗方案安全,并显示出合理的长期临床结局,但与单纯手术相似。

研究设计与样本

  • MISSILE 2期试验纳入诊断為T1-2N0M0非小细胞肺癌、体能状态良好且肺功能足够的患者,接受新辅助SABR后行肺叶或楔形切除。
  • 共40例入组患者接受SABR,其中36例后续接受手术。

主要发现

  • 病理完全缓解率为60%,主要完全缓解率为63%。
  • 手术后中位随访6.6年,5年总生存为66.7%(95%CI,48.8%-79.5%),5年无病生存为58.3%(95%CI,40.7%-72.4%),5年癌症特异性生存为76.4%(95%CI,58.2%-87.4%)。
  • 5年局部控制为93.5%(95%CI,76.3%-98.4%),5年区域控制为80.1%(95%CI,62.7%-90.0%),5年远处控制为82.4%(95%CI,64.9%-91.7%)。
  • SABR加手术后,16.7%(n=6)患者出现相关≥3级不良事件,无5级事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: For early-stage non-small cell lung cancer, surgery is the preferred approach in operable patients, whereas SABR is preferred for patients who are medically inoperable. The combination of neoadjuvant SABR followed by surgery was tested in the Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer (MISSILE) phase 2 trial. We report long-term outcomes beyond 5 years of follow-up. METHODS AND MATERIALS: Patients diagnosed with T1-2N0M0 non-small cell lung cancer with good performance status and adequate lung function were enrolled. Patients underwent neoadjuvant SABR followed by lobectomy/wedge resection. Forty enrolled patients received SABR, of which 36 patients proceeded to surgery. RESULTS: The pathologic and major complete response rates were 60% and 63%, respectively. Median follow-up was 6.6 years following surgery. Five-year overall, disease-free, and cancer-specific survival were 66.7% (95% CI, 48.8%-79.5%), 58.3% (95% CI, 40.7%-72.4%), and 76.4% (95% CI, 58.2%-87.4%), respectively. Five-year local, regional, and distant control were 93.5% (95% CI, 76.3%-98.4%), 80.1% (95% CI, 62.7%-90.0%), and 82.4% (95% CI, 64.9%-91.7%), respectively. After SABR and surgery, 16.7% (n = 6) of patients experienced related grade ≥3 adverse events, and there were no grade 5 events. CONCLUSIONS: The combined approach of SABR and surgery was safe and demonstrated reasonable long-term clinical outcomes, but similar to surgery alone.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tan VS, Correa RJM, Nguyen TK, et al. Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non-Small Cell Lung Cancer: Long-Term Clinical Outcomes. Int J Radiat Oncol Biol Phys. 2024. PMID: 39362312. doi:10.1016/j.ijrobp.2024.07.2332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。